Navigation Links
BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Date:1/19/2011

release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations related to regulatory actions on BMN 701 and the development and efficacy of BMN 701. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2009 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... LAS VEGAS , Jan. 23, 2015 Cord Blood ... CBAI ) ("CBAI" or the "Company")  filed a Preliminary Proxy ... ( www.sec.gov ) today, and provides an update for shareholders ... authorized shares is requested. Dear Shareholders, ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... Colo. , Jan. 22, 2015  BiOptix is pleased ... as Vice President of Chemistry and Biochemistry. Scott joins ... Pharmaceuticals, AstraZeneca Pharmaceuticals, and Amgen throughout the course of ... development. "Scott is a nationally recognized thought ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... - Drugs Target Gene Pathways to Preserve Heart, ... Researchers at The,Children,s Hospital of Philadelphia have ... blood flow to strongly protect heart,tissue in animal ... an,emergency treatment for heart attack patients, particularly since ...
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
Cached Medicine Technology:Novel Approach May Protect Against Heart Attack Injury 2Novel Approach May Protect Against Heart Attack Injury 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... Jolla, Calif. (PRWEB) January 22, 2015 ... Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) ... for their leadership in advancing biotechnology, biomedical science, ... Bonilla and Olsen each received the “2014 Life ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... Australian-based,natural health care products company that markets a range ... nature identical ingredients,announced today that its Quit Nits head ... United States through a distribution agreement with,CVS Pharmacies., ... agreement was the,result of two years of hard work ...
... identified a gene that is the key switch that ... , Much like students in a kindergarten class lining ... is identified as Smarcd3, must align correctly with two ... known as myogenesis, said principal investigator Monte Westerfield, a ...
... is a company with a renowned track record ... high throughput technologies. Genomatix algorithms include optimized fast ... complete genome annotation in terms of transcriptome and ... databases in this specific content by a factor ...
... of us probably don,t think much,about being regular, ... Johanson,practicing gastroenterologist at the Beloit Clinic in Beloit, ... health is that we,re,not getting enough fiber., ... http://media.medialink.com/WebNR.aspx?story=34435 Registered journalists can access video, ...
... the top killers in the country, but youd never know it ... of the Society for Critical Care Medicine (SCCM). , Research ... blood pressure, yet many of them dont even know it. ... the medications they need to control it," says Dr. Christopher Granger, ...
... improves access by ... care facilities and consumers, BUFFALO, N.Y., Jan. ... health care provider network to provide,routine wellness and ... the company announced today., HealthTransaction Network connects ...
Cached Medicine News:Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 2Health News:Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products 3Health News:Oregon researchers find trigger gene for muscle development 2Health News:Severe hypertension: 'Silent killer' still on the loose 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 2Health News:Buffalo Company Launches First-ever National Electronic Transaction Network to Improve Health Care Access for Uninsured and Underinsured 3
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
... were developed for situations were larger traction ... provided for with a standard halo crown ... four skull pins and S hook. Two, ... at 10 angle. Pressure indicating skull pins. ...
... access to the skull by trepanation. Excellent ... motor at standard operating pressure: 6 bars ... Full manual control by a progressive trigger. ... drilling speed of approx. 800 rpm. High ...
14 cm - 5 1/2, 6.0 mm , for drill handles and hand drills....
Medicine Products: